Part 1: Understanding Regulatory Requirements
In the fast-paced world of pharmaceuticals, ensuring the safety, efficacy, and quality of pharmaceutical products are paramount. Pharmaceutical quality assurance encompasses a range of activities aimed at maintaining and improving product quality throughout the product lifecycle from drug development, Phase I, II and III clinical trials, commercial manufacturing, packaging, and distribution processes, and ultimately product retirement. In this comprehensive guide, we will explore the essential steps to navigate pharmaceutical quality assurance effectively.
The world marketplace for drugs is large, with the majority of sales in three regions: 35% of the pharmaceutical market resided in the United States, 24% in Europe, 12% in Japan, with the remaining 29% in emerging markets based on 2019 data. Pharmaceuticals in all their forms compete today as part of a global market, serving different parts of the world’s population to varying extents.
The pharmaceutical industry is heavily regulated worldwide to ensure that products meet stringent quality standards and are safe for patient use. Regulatory bodies such as the FDA (Food and Drug Administration) in the United States, the EMA (European Medicines Agency) in Europe and the regulatory agencies in Asia-Pacific (APAC) region (including Japan, China, Australia, and New Zealand) set forth guidelines and requirements that must be followed. These regulations cover every aspect of pharmaceutical development, from clinical trials to manufacturing and distribution.
International regulatory harmonization is increasingly important given the complex, global and diverse nature of pharmaceutical industry operations. Different regulatory authorities often have different scientific and regulatory requirements that drug developers need to meet for product approval. This can lead to duplication of effort, increased costs, and time for the developer to bring the product to market, and slower patient access.
The United States Food and Drug Administration has been engaging with other regulatory and industry stakeholders worldwide to harmonize regulatory requirements across regions. A major part of FDA’s regulatory harmonization effort is undertaken through their work as a Founding Regulatory Member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). While US Regulations, as defined in the Food and Drug Act, and codified in the Federal Register Chapter 21 Code of Federal Regulations, subchapter C Drugs: General (including parts 210 and 211 current Good Manufacturing Practices for Drug Products) and subchapter F Biologics: parts 600-680 are followed for drug and biologic product development within the United States. The regulatory bodies within the United States, Europe and Japan determined thirty years ago that each regions requirements for drugs and biological product development and approval needed to be harmonized to allow for easier drug and biological product approvals in these various regions of the world.
In the 1980s the European Union began harmonizing regulatory requirements within member states, and in 1989, Europe, Japan, and the United States began creating plans for harmonization within their geographical spheres. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created in April 1990 at a meeting in Brussels. ICH had the initial objective of coordinating the regulatory activities of the European, Japanese and United States regulatory bodies in consultation with the pharmaceutical trade associations from these regions, to discuss and agree the scientific aspects arising from product registration.Since the new millennium, ICH’s attention has been directed towards extending the benefits of harmonization beyond the founding ICH region.
With the formation of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use as a legal entity in Switzerland in 2015, the aim of these reforms was to transform ICH into a truly global initiative supported by a robust and transparent governance structure. The ICH Association is now established as the over-arching governing body with the aim of focusing global pharmaceutical regulatory harmonization work in one venue that allows pharmaceutical regulatory authorities and concerned industry organizations to be more actively involved in ICH’s harmonization work.